Literature DB >> 32224733

Bariatric Surgery is Associated With Decreased Progression of Nonalcoholic Fatty Liver Disease to Cirrhosis: A Retrospective Cohort Analysis.

Keith M Wirth1,2, Adam C Sheka1,2, Scott Kizy1, Ryan Irey3, Ashley Benner4, Gretchen Sieger4, Gyorgy Simon3, Sisi Ma3, John Lake5, Constantin Aliferis3, Daniel Leslie1, Schelomo Marmor1, Sayeed Ikramuddin1,2.   

Abstract

OBJECTIVE: This study sought to compare trends in the development of cirrhosis between patients with NAFLD who underwent bariatric surgery and a well-matched group of nonsurgical controls. SUMMARY OF BACKGROUND DATA: Patients with NAFLD who undergo bariatric surgery generally have improvements in liver histology. However, the long-term effect of bariatric surgery on clinically relevant liver outcomes has not been investigated.
METHODS: From a large insurance database, patients with a new NAFLD diagnosis and at least 2 years of continuous enrollment before and after diagnosis were identified. Patients with traditional contraindications to bariatric surgery were excluded. Patients who underwent bariatric surgery were identified and matched 1:2 with patients who did not undergo bariatric surgery based on age, sex, and comorbid conditions. Kaplan-Meier analysis and Cox proportional hazards modeling were used to evaluate differences in progression from NAFLD to cirrhosis.
RESULTS: A total of 2942 NAFLD patients who underwent bariatric surgery were identified and matched with 5884 NAFLD patients who did not undergo surgery. Cox proportional hazards modeling found that bariatric surgery was independently associated with a decreased risk of developing cirrhosis (hazard ratio 0.31, 95% confidence interval 0.19-0.52). Male gender was associated with an increased risk of cirrhosis (hazard ratio 2.07, 95% confidence interval 1.31-3.27).
CONCLUSIONS: Patients with NAFLD who undergo bariatric surgery are at a decreased risk for progression to cirrhosis compared to well-matched controls. Bariatric surgery should be considered as a treatment strategy for otherwise eligible patients with NAFLD. Future bariatric surgery guidelines should include NAFLD as a comorbid indication when determining eligibility.

Entities:  

Mesh:

Year:  2020        PMID: 32224733     DOI: 10.1097/SLA.0000000000003871

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  8 in total

1.  Role of Indole-3-Acetic Acid in NAFLD Amelioration After Sleeve Gastrectomy.

Authors:  Yu Wang; Geng Wang; Jie Bai; Ning Zhao; Qingbo Wang; Rui Zhou; Gang Li; Chaojie Hu; Xin Li; Kaixiong Tao; Zefeng Xia; Guobin Wang
Journal:  Obes Surg       Date:  2021-05-10       Impact factor: 4.129

Review 2.  Metabolic Surgery: Paradigm Shift in Metabolic Syndrome/Diabetes Therapy.

Authors:  Annika Rühle; Adrian T Billeter; Beat P Müller-Stich
Journal:  Visc Med       Date:  2022-01-20

Review 3.  Comparative effectiveness of medical treatment vs. metabolic surgery for histologically proven non-alcoholic steatohepatitis and fibrosis: a matched network meta-analysis.

Authors:  Adrian T Billeter; Beatrice Reiners; Svenja E Seide; Pascal Probst; Eva Kalkum; Christian Rupp; Beat P Müller-Stich
Journal:  Hepatobiliary Surg Nutr       Date:  2022-10       Impact factor: 8.265

4.  Comparison of Liver Recovery After Sleeve Gastrectomy and Roux-en-Y-Gastric Bypass.

Authors:  Sophia M-T Schmitz; Andreas Kroh; Alexander Koch; Jonathan F Brozat; Christine Stier; Ulf P Neumann; Tom F Ulmer; Patrick H Alizai
Journal:  Obes Surg       Date:  2021-04-04       Impact factor: 4.129

Review 5.  Obesity Management in the Primary Prevention of Hepatocellular Carcinoma.

Authors:  Elizabeth R M Zunica; Elizabeth C Heintz; Christopher L Axelrod; John P Kirwan
Journal:  Cancers (Basel)       Date:  2022-08-22       Impact factor: 6.575

Review 6.  Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality.

Authors:  Yi Xia; Mengting Ren; Jinpu Yang; Changzhou Cai; Weixin Cheng; Xinxin Zhou; Dan Lu; Feng Ji
Journal:  Front Microbiol       Date:  2022-09-20       Impact factor: 6.064

Review 7.  Gut Microbiome and Metabolites in Patients with NAFLD and after Bariatric Surgery: A Comprehensive Review.

Authors:  Jacqueline Hoozemans; Maurits de Brauw; Max Nieuwdorp; Victor Gerdes
Journal:  Metabolites       Date:  2021-05-31

Review 8.  Peroxisome Proliferator-Activated Receptors and Their Novel Ligands as Candidates for the Treatment of Non-Alcoholic Fatty Liver Disease.

Authors:  Anne Fougerat; Alexandra Montagner; Nicolas Loiseau; Hervé Guillou; Walter Wahli
Journal:  Cells       Date:  2020-07-08       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.